Okitsu-Negishi S, Furusawa S, Kawa Y, Hashira S, Ito S, Hiruma F, Mizoguchi M, Yoshino K, Abe T
Department of Pediatrics, Teikyo University School of Medicine, Tokyo, Japan.
Immunol Res. 1994;13(1):49-55. doi: 10.1007/BF02918224.
In order to study the effect of human immunoglobulin preparations for intravenous use (IVIg) on the production and activity of interleukin-1 (IL-1) derived from monocytes, we treated cultured monocytes with IVIg and examined the lymphocyte-activating factor (LAF) activity of IL-1 in the culture supernatants. The results showed that IVIg suppressed the activity from most healthy adults and some febrile children with acute respiratory disease or Kawasaki disease. Further studies revealed that intact Ig (whole molecular Ig) did not suppress the mRNA expression of IL-1 alpha or IL-1 beta in mononuclear cells, that intact Ig and pepsin-digested Ig inhibited the LAF activity of recombinant IL-1 (rIL-1) and also that intact Ig contains immunoglobulin (probably anti-IL-1 antibody) which binds with rIL-1 by dot blotting using biotin-streptavidin. These results suggest that IVIg suppresses neither IL-1 synthesis nor the release of IL-1 from monocytes but does neutralize IL-1 alpha and IL-1 beta activity by binding IL-1 proteins as an anti-IL-1 antibody.
为了研究静脉用人免疫球蛋白制剂（IVIg）对单核细胞衍生的白细胞介素-1（IL-1）产生及活性的影响，我们用IVIg处理培养的单核细胞，并检测培养上清液中IL-1的淋巴细胞激活因子（LAF）活性。结果显示，IVIg抑制了大多数健康成年人以及一些患有急性呼吸道疾病或川崎病的发热儿童的该活性。进一步研究表明，完整Ig（全分子Ig）不抑制单核细胞中IL-1α或IL-1β的mRNA表达，完整Ig和胃蛋白酶消化的Ig均抑制重组IL-1（rIL-1）的LAF活性，并且完整Ig含有通过生物素-链霉亲和素斑点印迹与rIL-1结合的免疫球蛋白（可能是抗IL-1抗体）。这些结果表明，IVIg既不抑制IL-1的合成，也不抑制单核细胞释放IL-1，但确实通过作为抗IL-1抗体结合IL-1蛋白来中和IL-1α和IL-1β的活性。
